Co-infections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study.

The Lancet. Microbe
C. D. RussellISARIC4C investigators

Abstract

Microbiological characterisation of co-infections and secondary infections in patients with COVID-19 is lacking, and antimicrobial use is high. We aimed to describe microbiologically confirmed co-infections and secondary infections, and antimicrobial use, in patients admitted to hospital with COVID-19. The International Severe Acute Respiratory and Emerging Infections Consortium (ISARIC) WHO Clinical Characterisation Protocol UK (CCP-UK) study is an ongoing, prospective cohort study recruiting inpatients from 260 hospitals in England, Scotland, and Wales, conducted by the ISARIC Coronavirus Clinical Characterisation Consortium. Patients with a confirmed or clinician-defined high likelihood of SARS-CoV-2 infection were eligible for inclusion in the ISARIC WHO CCP-UK study. For this specific study, we excluded patients with a recorded negative SARS-CoV-2 test result and those without a recorded outcome at 28 days after admission. Demographic, clinical, laboratory, therapeutic, and outcome data were collected using a prespecified case report form. Organisms considered clinically insignificant were excluded. We analysed data from 48 902 patients admitted to hospital between Feb 6 and June 8, 2020. The median patient age was 74 year...Continue Reading

References

Aug 26, 2011·Rheumatology·Veronika R LangJochen Zwerina
Sep 27, 2013·Influenza and Other Respiratory Viruses·Carol JosephNahoko Shindo
May 28, 2016·Influenza and Other Respiratory Viruses·Eili Y KleinAndrea Dugas
May 13, 2019·Journal of Biomedical Informatics·Paul A HarrisUNKNOWN REDCap Consortium
Apr 12, 2020·Respirology : Official Journal of the Asian Pacific Society of Respirology·Robert J Lentz, Henri Colt
May 24, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Xiaomin LuoWeize Yang
Jul 28, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Bradley J LangfordNick Daneman
Aug 7, 2020·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Kyra Y L ChuaJason A Trubiano
Aug 19, 2020·Journal of Medical Virology·Alvaro Goncalves Mendes NetoZurab Azmaiparashvili
Oct 4, 2020·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Elske SieswerdaW Joost Wiersinga
Oct 13, 2020·The Journal of Hospital Infection·Chris LynchJim Gray
Dec 4, 2020·Open Forum Infectious Diseases·Jaclyn A CusumanoDeena R Altman
Jan 9, 2021·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·Bradley J LangfordDerek R MacFadden
Jan 20, 2021·The Journal of Antimicrobial Chemotherapy·Claire Y MasonGabriele Pollara
Sep 6, 2019·JAC-antimicrobial Resistance·Clark D RussellClaire L Mackintosh

❮ Previous
Next ❯

Citations

Aug 24, 2021·Clinical and Experimental Medicine·Amir AbdoliAzra Kenarkoohi
Aug 28, 2021·Antibiotics·Santiago GrauUNKNOWN Catalan Infection Control and Antimicrobial Stewardship Program (VINCat-PROA)
Jul 8, 2021·The Lancet. Microbe·Abi ManeshUNKNOWN CENDRIC Investigators and Collaborators
Aug 31, 2021·Beni-Suef University Journal of Basic and Applied Sciences·Ranjan K MohapatraLucia Pintilie
Sep 2, 2021·The Lancet. Microbe·Tom G S WilliamsGeraldine A O'Hara
Aug 20, 2021·Journal of Internal Medicine·Trine KåsineUNKNOWN NOR-Solidarity Study Group
Aug 26, 2021·American Journal of Respiratory and Critical Care Medicine·Georgios D Kitsios, Alison Morris
Nov 9, 2021·Annals of Internal Medicine·Timothy M Uyeki
Nov 10, 2021·Current Opinion in Infectious Diseases·Alexis TabahJean-François Timsit
Oct 2, 2021·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Nina ZhuAlison Holmes

❮ Previous
Next ❯

Software Mentioned

REDCap
finalfit
R
fuzzyjoin
stringdist
AWaRe
Tidyverse

Related Concepts

Related Feeds

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.